{
  "abstract": "Early in the 20th century, Osler published his famous Law of life: ‘…no two individuals react alike under the abnormal conditions which we know as disease’. Cystic fibrosis (CF) obeys this law, people sharing identical CFTR gene variants often differing in phenotype.1 CFTR modulators were the first drugs to restore CFTR protein function through stabilisation (correctors) and channel activity (potentiators). Combinations, both dual and more so triple, have demonstrated multi-organ benefits. 2 However, around mean improvements in pulmonary outcomes and sweat chloride (diagnostic hallmark/CFTR functional biomarker), interindividual variability is a poorly understood characteristic of most studies.",
  "authors": [
    {
      "affiliations": [
        "National Heart and Lung Institute, Imperial College London Faculty of Medicine, London, England, UK",
        "Royal Brompton Hospital, Part of Guy's and St Thomas’ NHS Foundation Trust, London, England, UK"
      ],
      "name": "Jane Carolyn Davies"
    },
    {
      "affiliations": [
        "National Heart and Lung Institute, Imperial College London Faculty of Medicine, London, England, UK",
        "Royal Brompton Hospital, Part of Guy's and St Thomas’ NHS Foundation Trust, London, England, UK"
      ],
      "name": "Gemma Wilson"
    },
    {
      "affiliations": [
        "National Heart and Lung Institute, Imperial College London Faculty of Medicine, London, England, UK",
        "Royal Brompton Hospital, Part of Guy's and St Thomas’ NHS Foundation Trust, London, England, UK"
      ],
      "name": "Dominic Hughes"
    }
  ],
  "title": "Variability: the law of life?",
  "uid": "644ae3c5-eab9-528f-8b49-e7386e507611"
}